Classification and comparison of oral contraceptives containing new generation progestogens

Human Reproduction Update

Volumn 1, Issue 3, 1995, Pages 231-263

  Newton, J R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Classification; Desogestrel; Gestodene; Norgestimate; Oral contraceptives

Indexed keywords

ANDROGEN; DESOGESTREL; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; SEX HORMONE BINDING GLOBULIN;

BLOOD; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; HUMAN; METABOLISM; REVIEW; STANDARD;

ANDROGENS; CHOLESTEROL, HDL; CONTRACEPTIVES, ORAL; DESOGESTREL; FEMALE; HUMANS; NORPREGNENES; PROGESTINS; SEX HORMONE-BINDING GLOBULIN;

EID: 0029295069     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/1.3.231     Document Type: Article

References (302)

1. Ahbate, R., Pinto, S., Rostagno, C., Bruni, V., Rosati, D. and Mariani, G. (1990) Effects of long-term gestodene-containing oral contraceptive administration on hemostasis. Am. J. Obstet. Gynecol., 163, 424–430.
2. Adams, M.R., Wagner, J.D., Washburn, S.A. and Clarkson, T.B. (1991) The effects of contraceptive steroids on atherosclerosis: experimental evidence. Adv. Contracept., 7 (Suppl. 3), 227–234.
3. Affinito, P., Monterubbianesi, M., Primizia, M., Regine, V., Di Carlo, C., Farace, M.J., Petrillo, G. and Nappi, C. (1993) Efficacy, cycle control and side effects of two monophasic combination oral contraceptives: gestodene/ethinyl estradiol and norgestimate/ethinyl estradiol. Gynecol. Endocrinol., 7, 259–266.
4. Agoestina, T., Sabarudin, U. and Hoppe, G. (1989) A study comparing a gestoden triphasic formulation with a fixed combination OC. Adv. Contracept., 5, 71–84.
5. Åkerlund, M., Røde, A. and Westergaard, J. (1993) Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol. Br. J. Obstet. Gynaecol., 100, 832–838.
6. Åkerlund, M., Almström, E., Högstedt, S. and Nabrink, M. (1994) Oral contraceptives containing 20 and 30 μg of ethinyl estradiol with 150 μg desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet. Gynecol. Scand., 73, 136–143.
7. Allen, B.S. and Smith, G. (1982) Various parameters for grading acne vulgaris. Arch. Dermatol., 118, 23–25.
8. Alton, K.B., Heytei, N.S., Shaw, C. and Patrick, J.E. (1984) Biotransformation of norgestimate in women. Contraception, 29, 19–29.
9. Anderson, D.C. (1974) Sex hormone binding globulin. Clin. Endocrinol., 3, 69–96.
10. Andolsek, K.M. (1992) Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet. Gynecol. Scand, Suppl., 156, 22–26.
11. Archer, D.F., Timmer, C.J. and Lammers, P. (1994) Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol. Fertil. Steril., 61, 645–651.
12. Aznar-Ramos, R., Giner-Velazquez, J., Lara-Ricalde, R. and Martinez-Manatou, J. (1969) Incidence of side effects with contraceptive placebo. Am. J. Obstet. Gynecol., 105, 1144–1149.
13. Azziz, R. and Gay, F. (1989) The treatment of hyperandrogenism with oral contraceptives. Semin. Reprod. Endocrinol., 7, 246–254.
14. Back, D.J., Grimmer, S.F.M., Shenoy, N. and Orme, M.L.E. (1987) Plasma concentrations of 3-ketodesogestrel after oral administration of desogestrel and intravenous administration of 3-ketodesogestrel. Contraception, 35, 619–626.
15. Back, D.J., Ward, S. and Orme, M.L.E. (1991) Recent pharmacokinetic studies of low-dose oral contraceptives. Adv. Contracept., 7 (Suppl. 3), 164–179.
16. Badimon, J.J., Badimon, L. and Fuster, V. (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J. Clin. Invest., 85, 1234–1241.
17. Ball, M.J., Ashwell, E., Jackson, M.C., Carter, R. and Gillmer, M.D.G. (1989) Which pill? The effect of various modem preparations on lipoproteins and glucose metabolism. Br. J. Fant. Plann., 14, 110–115.
18. Ball, M.J., Ashwell, E., Jackson, M. and Gillmer, M.D.G. (1990) Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins. Contraception, 41, 363–377.
19. Barranco, V.P. (1974) Effect of androgen-dominant and estrogen-dominant oral contraceptives on acne. Cutis, 14, 384–386.
20. Barranco, V.P. and Jones, D.D. (1974) Effect of oral contraceptives on acne. South. Med. J., 67, 703–706.
21. Basdevant, A., Conard, J., Pelissier, C., Guyene, T.T., Lapousterle, C., Mayer, M., Guy-Grand, B. and Degrelle, H. (1993) Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception, 48, 193–204.
22. Becker, H. (1990) Supportive European data on new oral contraceptive containing norgestimate. Acta Obstet. Gynecol. Scand., Suppl., 152, 33–39.
23. Belsey, E.M. and Farley, T.M.M. (1988) The analysis of menstrual bleeding patterns: a review. Contraception, 38, 129–156.
24. Belsey, E.M. and The Task Force on Long-Acting Systemic Agents for Fertility Regulation (1991) Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Adv. Contracept., 7, 257–270.
25. Benagiano, G. (1989) Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol. Int. J. Fertil., 34, 31–39.
26. Benagiano, G., Primiero, F.M., Bastianeili, C., Abbondante, G., Grottanelli, F. and Tunnera, G. (1990) Ovarian activity during oral contraception. Adv. Contracept., 6, 245.
27. Bergink, E.W., Borglin, N.E, Klottrup, P. and Liukko, P. (1982) Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives in serum lipoproteins. Contraception, 25, 477–485.
28. Bergink, E.W., Kloosterboer, H.J., Lund, L. and Nummi, S. (1984) Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-1 and B and glycosylated proteins. Contraception, 30, 61–72.
29. Bergink, W., Assendorp, R., Kloosterboer, L., van Lier, W., Voortman, G. and Qvist, I. (1990) Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestagens to sex hormone-binding globulin. Am. J. Obstet. Gynecol., 163, 2132–2137.
30. Bertolini, S., Elicio, N., Cordera, R., Gapitanio, G.L., Montagna, G., Croce, S., Saturnino, M., Balestreri, R. and de Cecco, L. (1987) Effects of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstet. Gynecol. Scand., 66, 327–332.
31. Bilotta, P. and Favilli, S. (1988) Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Arzneim.-Forsch., 38, 932–934.
32. Blankenhorn, D.H., Johnson, R.L., Nessim, S.A., SanMarco, M.E, Azen, S.P. and CashinrHemphill, L. (1987) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J. Am. Med. Assoc., 257, 3233–3240.
33. Böcker, R., Kleingeist, B., Eichhorn, M. and Lepper, H. (1991) In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv. Contracept., 7, 140–148.
34. Bonnar, J. (1987) Coagulation effects of oral contraception. Am. J. Obstet. Gynecol., 157, 1042–1048.
35. Bonnar, J. (1991) Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv. Contracept., 7 (Suppl. 3), 285–291.
36. Brien, T.G. (1981) Human corticosteroid binding globulin. Clin. Endocrinol., 14, 193–212.
37. Brill, K., Schnitker, J. and Albring, M. (1990) Long-term experience with a low-dose oral contraceptive. Clin. Endocrinol., 4, 277–286.
38. Brill, K., Müller, C., Schnitker, J. and Albring, M. (1991) The influence of different modem low-dose oral contraceptives on intermenstrual bleeding. Adv. Contracept., 7 (Suppl. 2), 51–61.
39. Brown, G., Albers, J.J., Fisher, L.D., Schaeffer, S.M., Lin, J.-T., Kaplan, C., Zhao, X.Q., Bisson, B.D., Fitzpatrick, V.F. and Dodge, H.T. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289–1298.
40. Bruni, V., Rosati, D., Bucciantini, S., Verni, A., Abbate, R., Costanzo, M., Pinto, S. and Costanzo, G. (1987) Desogestrel in monophasic E/P combination: monitoring of endocrine parameters and evaluation of hemostatic function. Acta Eur. Fertil., 18, 277–280.
41. Buchwald, H., Campos, C.T., Matts, J.P., Fitch, L.L., Long, J.M. and Vasco, R.L. (1992) Women in the POSCH trial. Effects of agressive cholesterol modification in women with coronary heart disease. Ann. Surg., 216, 389–400.
42. Burkman, R.T., Kafrissen, M.E, Olson, W. and Osterman, J. (1992) Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet. Gynecol. Scand., Suppl., 156, 5–8.
43. Bush, T.L., Barren-Connor, E, Cowan, L.D., Criqui, M.H., Wallace, R.B., Suchindram, C.M., Tyroler, H.A. and Rifkind, B.M. (1987) Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinic’s Program Follow-Up Study. Circulation, 75, 1002–1009.
44. Carpenter, S. and Neinstein, L.S. (1986) Weight gain in adolescent and young adult oral contraceptive users. J. Adolesc. Health Care, 7, 342–344.
45. Carr, B.R. (1993) Cycle control with desogestrel-containing oral contraceptives — comparison of a monophasic and triphasic regimen. Int. J. Fertil., 38, 274–279.
46. Cohen, H., Mackie, I.J., Walshe, K., Gillmer, M.D.G. and Machin, S.J. (1988) A comparison of the effects of two triphasic oral contraceptives on hemostasis. Br. J. Haematol., 69, 259–263.
47. Consensus Development Meeting (1990) Metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am. J. Obstet. Gynecol., 162, 1335–1337.
48. Corson, S.L. (1990) Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet. Gynecol. Scand, Suppl., 152, 25–31.
49. Creatsas, G., Adamopoulos, P., Eleftheriou, N., Deligeoroglou, E., Arefetz, N., Koumantakis, E, Goumalatsos, N. and Loutradis, D. (1991) Clinical and metabolic effects of the monophasic gestodene/ethinylestradiol pill for contraception during adolescence. Adolesc. Pediatr. Gynecol., 4, 76–81.
50. Crona N., Silfverstolpe, G. and Samsioe, G. (1985) The effects of two gonane progestins alone and in combination with ethinyl estradiol on serum lipoproteins. Eur. J. Obstet. Gynecol. Reprod. Biol., 19, 365–374.
51. Crook, D., Godsland, I.F., Worthington, M., Felton, C.V., Proudler, A.J. and Stevenson, J.C. (1993) A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desgestrel or gestodene progestins. Am. J. Obstet. Gynecol., 169, 1183–1189.
52. Crosignani, P.G., Finelli, F. and Pizzi, C. (1992) Multicenter clinical trials on triphasic gestodene. In Genazzani, A.R. and Skouby, S.O. (eds). Triphasic Gestodene — A New Approach to Oral Contraception. Parthenon Publishing, Camforth, UK, pp. 77–89.
53. Cullberg, J. (1972) Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double-blind comparison with a placebo. Acta Psychiatr. Scand., Suppl., 236, 259–276.
54. Cullberg, G., Dovré, P.A., Lindstedt, G. and Steffensen, K. (1982a) On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet. Gynecol. Scand., Suppl., 111, 47–54.
55. Cullberg, G., Samsioe, G., Andersen, R.F., Bredesgaard, P., Andersen, N.B., Emerot, H., Fanoee, E., Fylling, P., Haach-Sorensen, P.E., Klottnip, P., Pedersen, J.H. and Sandager, T. (1982b) Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. Contraception, 26, 229–243.
56. Cullberg, G., Hamberger, L., Mattsson, L.A., Mobacken, H. and Samsioe, G. (1985a) Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination. Acta Obstet. Gynecol. Scand, 64, 203–207.
57. Cullberg, G., Hamberger, L., Mattsson, L.A., Mobacken, H. and Samsioe, G. (1985b) Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome. Acta Obstet. Gynecol. Scand., 64, 195–202.
58. Daly, L. and Bonnar, J. (1990) Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets. Am. J. Obstet. Gynecol., 163, 430–437.
59. Damey, P. (1993) Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials. Contraception, 48, 323–337.
60. Daume, E (1990) Influence of modem low-dose oral contraceptives on hemostasis. Adv. Contracept., 6, 51–68.
61. David, J.L., Gaspard, U.J., Gillain, D., Raskinet, R. and Lepot, M.R. (1990) Hemostasis profile in women taking low-dose oral contraceptives. Am. J. Obstet. Gynecol., 163, 420–423.
62. de Aloysio, D., Mauloni, M., Roncuzzi, A., Altieri, P., Bottiglioni, F., Trossarelli, G.F., Fanizza, G. and Covelli, A. (1993) Effects of an oral contraceptive combination containing 0.150 μg desogestrel plus 0.020 μg ethinyl estradiol on healthy premenopausal women. Arch. Gynecol. Obstet., 253, 15–19.
63. Delahunt, J.W. (1993) Hirsutism — practical therapeutic guidelines. Drugs, 45, 223–231.
64. DeLeo, V., Lanzetta, D., Vanni, A.L., D’Antona, D. and Seven, F.M. (1991) Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception, 44, 155–161.
65. Dewis, P., Petsos, P., Newman, M. and Anderson, D.C. (1985) The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol. Clin. Endocrinol., 22, 29–36.
66. Djbbelt, L., Knuppen, R., JQtting, G., Heimann, S., Klipping, C.O. and Parikka-Olexik, H. (1991) Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months. Contraception, 43, 1–21.
67. Dibbelt, L., Knuppen, R., Kuhnz, W. and Jütting, G. (1992) Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months. Arzneim.-Forsch., 42, 1146–1152.
68. Dickey, R.P. and Stone, S.C. (1976) Progestational potency of oral contraceptives. Obstet. Gynecol., 47, 106–112.
69. Dieben, T.O.M. and van Beek, A. (1986) Desogestrel-containing oral contraceptives and blood pressure. Arzneim.-Forsch., 36, 1678–1680.
70. Dieben, T.O.M., van Beek, A. and Coelingh Bennink, H.J.T. (1991) Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Arzneinu-Forsch., 41, 996–998.
71. Dieben, T.O.M., Vromans, L., Theeuwes, A. and Coelingh Bennink, H.J.T. (1994) The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception, 50, 373–382.
72. Düsterberg, B., Tack, J.W., Krause, W. and Hümpel, M. (1987) Pharmacokinetics and biotransformation of gestodene in man. In Elstein, M. (ed.), Gestodene, Development of a New Gestodene-Containing Low-Dose Oral Contraceptive. Parthenon Publishing, Carnforth, UK, pp. 35–44.
73. Elstein, M. (1994) Concensus paper: Low dose contraceptive formulations: is further reduction in steroid dosage justified? Adv. Contracept., 10, 1–4.
74. Engel, H.J. (1991) Angiographic findings after myocardial infarctions of young women: role of oral contraceptives. Adv. Contracept., 7 (Suppl. 3), 235–243.
75. Erkkola, R., Hirvonen, E., Luikko, J., Lumme, R., Männikkö, H. and Aydinlik, S. (1990) Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet. Gynecol. Scand., 69, 61–65.
76. Falsetti, L. (1991) Acne treatment with a new estroprogestinic biphasic combination containing desogestrel. Acta Eur. Fertil., 22, 283–286.
77. Falsetti, L., Schivardi, M.R. and Prandini, B.D. (1987) A new low-dose estrogen oral contraceptive combination: effect on endocrine parameters and lipid status. Contraception, 36, 489–497.
78. Fioretti, P., Fruzzetti, F., Navalesi, R., Ricci, C., Miccoli, R., Cerri, M., Orlandi, M.C. and Melis, G.B. (1987) Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 μg desogestrel. Contraception, 35, 229–243.
79. Fioretti, P., Fruzzetti, F., Navalesi, R., Ricci, C., Miccoli, R., Cerri, M. and Melis, G.B. (1989) Clinical and metabolic effects of a pill containing 30 mcg ethinylestradiol plus 75 mcg gestodene. Contraception, 40, 649–663.
80. Fisch, I.R and Frank, J. (1977) Oral contraceptives and blood pressure. J. Am. Med. Assoc., 237, 2499–2503.
81. Fitzgerald, C., Feichtinger, W., Spona, J., Elstein, M., Lüdicke, F., Müller, U. and Williams, C. (1994) A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv. Contracept., 10, 5–18.
82. Fotherby, K. (1985) Oral contraceptive, lipids and cardiovascular disease. Contraception, 31, 367–394.
83. Fotherby, K, (1990a) Potency and pharmacokinetics of gestagens. Contraception, 41, 533–550.
84. Fotherby, K. (1990b) Update on lipid metabolism and oral contraception. Br. J. Fam. Plann., 15, 23–26.
85. Fotherby, K., Trayner, I., Longthome, P.N., Lee, B. and Watson, H.R. (1987) Metabolic investigations with Femodene — an oral contraceptive containing gestodene and ethinyloestradiol. Contraception, 35, 323–339.
86. Fruzzetti, F., Ricci, C., Nicoletti, I. and Fioretti, P. (1992) Clinical and metabolic effects of a triphasic pill containing gestodene. Contraception, 46, 335–347.
87. Gaspard, U. and Lefebre, P.J. (1990) Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J. Obstet. Gynecol., 163, 334–343.
88. Gaspard, U.J., Romus, M.A., Gillain, D., Duvivier, J., Demey-Ponsart, E. and Franchimont, P. (1983) Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception, 27, 577–590.
89. Gaspard, U.J., Buret, J., Gillain, D., Romus, M.A. and Lambotte, R. (1985) Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Contraception, 31, 395–408.
90. Gauthier, A., Upmalis, D. and Dain, M.P. (1992) Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. Acta Obstet. Gynecol. Scand., Suppl., 156, 27–32.
91. Geissler, K.H. and Ballmer, F. (1989) Einfluss einer Kombination von Desogestrel und Ethinylestradiol auf Akne vulgaris bei Frauen mit Kontrazeptionswunsch. Gyndkologe, 2, 321–324.
92. Gerstman, B.B., Piper, J.M., Tomita, D.K., Ferguson, W.J., Stadel, B.V. and Lundin, F.E. (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol., 133, 32–37.
93. Gevers Leuven, J.A., Dersjant-Roorda, M.C., Heimerhorst, F.M., de Boer, R., Neymeyer-Leloux, A. and Havekes, L. (1990a) Estrogenic effect of gestodene or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am. J. Obstet. Gynecol., 163, 358–362.
94. Gevers Leuven, J.A., Kluft, C., Dersjant-Roorda, M.C., Harthoom-Lasthuizen, E.J., Peters, F.P.A.M.N., Bernsen, M.J. and Heimerhorst, F.M. (1990b) Changes in coagulation and fibrinolysis variables during the use of two oral contraceptives containing the same dose of ethinyl estradiol and either gestodene or desogestrel. Adv. Contracept., 6, 69–73.
95. Gibbs, W.P. (1974) Acne and Ovral. Arch. Dermatol., 109, 912.
96. Godsland, I.F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport M. and Wynn, V. (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med., 323, 1375–1381.
97. Godsland, I.F., Walton, C., Felton, C., Proudler, A., Patel, A. and Wynn, V. (1991) Insulin resistance, secretion, and metabolism in users of oral contraceptives. J. Clin. Endocrinol Metab., 74, 64–70.
98. Godsland, I.F., Crook, D., Worthington, M., Proudler, A.J., Felton, C., Sidhu, M. and Stevenson, J.C. (1993) Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism. Contraception, 48, 217–227.
99. Goldhaber, S.Z., Hennekens, C.H., Spark, R.F., Evans, D.A., Rosner, B., Taylor, J.O. and Kass, E.H. (1984) Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am. Heart J., 107, 119–122.
100. Goldzieher, J.W., Moses, L.E and Averkin, E. (1971) A placebo-controlled double-blind cross-over investigation of the side-effects attributed to oral contraceptives. Fertil. Steril., 22, 609–623.
101. Goldzieher, J.W., Chenault C.B., Woutersz, T.B., Schneider, B.E. and Hansen, P.R. (1980) Clinical effects of ethynyl estrogens, used with and without progestational agents, on bleeding patterns, weight and blood pressure. Contraception, 22, 369–381.
102. Granata, A., Sobbrio, G.A., D’Arrigo, F., Barillari, M., Curasi, M.P., Egitto, M., Trimarchi, F., Granese, D. and Pulle, C. (1990) Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Acta Eur. Fertil., 21, 143–146.
103. Granata, A., Sobbrio, G.A., D’Arrigo, F., Barillari, M., de Luca, P., Egitto, M., Granese, D., Pulle, C. and Trimarchi, F. (1991) Changes in the plasma levels of proteins C and S in young women on low-dose oestrogen oral contraceptives. Clin. Exp. Obstet. Gynecol., 18, 9–12.
104. Greenberg, G., Imeson, J.D., Thompson, S.G. and Meade, T.W. (1985) Blood pressure and the menstrual cycle. Br. J. Obstet. Gynaecol., 92, 1010–1014.
105. Grimes, D.A., Godwin, A.J., Rubin, A., Smith, J.A. and Lacarra, M. (1994) Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet. Gynecol., 83, 29–34.
106. Guengerich, E.P. (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450iiiA4 by gestodene. Chem. Res. Toxicol., 3, 363–371.
107. Guillebaud, J. (1987) The forgotten pill — and the paramount importance of the pill-free week. Br. J. Fam. Plann., 12 (Suppl. 4), 35–43.
108. Guillebaud, J. (1989) Practical prescribing of the combined oral contraceptive pill. In Filshie, M. and Guillebaud, J. (eds). Contraception — Science and Practice. Butterworths, London, UK, pp. 69–93.
109. Hamilton, C.J.C.M. and Hoogland, H.J. (1989) Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am. J. Obstet. Gynecol., 161, 1159–1162.
110. Hammerstein, J., Daume, E., Simon, A., Winkler, U.H., Schindler, A.E., Back, D.J., Ward, S. and Neiss, A. (1993) Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary Cortisol and 6-hydroxycortisol. Contraception, 47, 263–281.
111. Hammond, G.L., Langley, M.S., Robinson, P.A., Nummi, S. and Lund, L. (1984) Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil. Steril., 42, 44–51.
112. Hammond, G.L., Bocchinfuso, W.P., Orava, M., Smith, C.L., van den Ende, A. and van Enk, A. (1994) Serum distribution and pharmacokinetics of two contraceptive progestins: 3-ketodesogestrel and gestodene. Contraception, 50, 301–308.
113. Harvengt, C., Desager, J.P., Gaspard, U. and Lepot, M. (1988) Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins. Contraception, 37, 565–575.
114. Hasenack, H.G., Bosch, A.M.G. and Käär, K. (1986) Serum levels of 3-ketodesogestrel after oral administration of desogestrel and 3-ketodesogestrel. Contraception, 33, 591–596.
115. Heber, K.R. (1971) Norgestrel and acne. Med. J. Aust., 2, 594.
116. Hedon, B., Cristol, P., Plauchut, A., Vallon, A.M., Desachampts, F. and Taillant, M.L. (1992) Ovarian consequences of the transient interruption of combined oral contraceptives. Int. J. Fertil., 37, 270–276.
117. Herold, E.S. and Goodwin, M.S. (1980) Perceived effects of oral contraceptives among adolescent girls. Can. Med. Assoc. J., 123, 1022–1023.
118. Ho, P.C., Liu, W.T. and Kwan, M.S.W. (1990) Serum lipids in Chinese patients using oral contraceptive pills. Contraception, 41, 55–61.
119. Hoppe, G. (1988) Gestodene, an innovative progestogen. Contraception, 37, 493–501.
120. Huber, J. (1991) Clinical experience with a norgestimate-containing oral contraceptive. Int. J. Fertil., 36, 25–31.
121. Hümpel, M., Tauber, U., Kuhnz, W., Pfeffer, M., Brill, K., Heithecker, R., Louton, T. and Steinberg, B. (1990) Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and Cortisol levels in women using two low-dose combined oral contraceptives. Horm. Res., 33, 35–39.
122. Inauen, W., Stocker, G., Häberli, A. and Straub, P.W. (1991) Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood. Contraception, 43, 435–446.
123. Inman, W.H.W. and Vessey, M.P. (1968) Investigation of deaths from pulmonary, coronary, and cerebral thrombosis in women of child-bearing age. Br. Med. J., 2, 193–199.
124. Inman, W.H.W., Vessey, M.P., Westerholm, B. and Engelund, A. (1970) Thromboembolic disease and the steroidal content of oral contraceptives — a report to the Committee on Safety of Drugs. Br. Med. J., 2, 203–209.
125. Jacobs, D.R., Mebane, I.L., Bangdiwala, S.I., Criqui, M.H. and Tyroler, H.A. (1990) High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinic’s Prevalence Study. Am. J. Epidemiol., 131, 32–47.
126. Janaud, A., Rouffy, J., Upmalis, D. and Dain, M.P. (1992) A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet. Gynecol. Scand., Suppl., 156, 33–38.
127. Jandrain, B.J., Humbiet, D.M.P., Jaminet, C.B., Scheen, A.J., Gaspard, U.J. and Lefebre, P.J. (1990) Effectl of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial. Am. J. Obstet. Gynecol., 163, 378–381.
128. Juchem, M., Pollow, K., Elger, W., Hoffmann, G. and Möbus, V. (1993) Receptor binding of norgestimate — a new orally active synthetic progestational compound. Contraception, 47, 283–294.
129. Jung-Hoffmann, C. and Kuhl, H. (1987) Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am. J. Obstet. Gynecol., 156, 199–203.
130. Jung-Hoffmann, C. and Kuhl, H. (1989) Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception, 40, 299–312.
131. Jung-Hoffmann, C., Heidt, F. and Kuhl, H. (1988a) Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception, 38, 593–603.
132. Jung-Hoffmann, C., März, W., Heidt, F., Gross, W. and Kuhl, H. (1988b) Der Effect zweier niederig-dosierter Gestoden oder Desogestrel enthaltender Ovulationshemmer auf die Sexualhormone und den Fettstoffwechsel. Geburtshilfe Frauenheilkd., 48, 215–219.
133. Jung-Hoffmann, C., Fitzner, M. and Kuhl, H. (1991) Oral contraceptives containing 20 or 30 ng ethinyl estradiol and 150 μg desogestrel: pharmacokinetics and pharmacodynamic parameters. Horm. Res., 36, 238–246.
134. Jung-Hoffmann, C., Storch, A. and Kuhl, H. (1992) Serum concentrations of ethinylestradiol, 3-keto-desogestrel, SHBG, CBG and gonadotropins during treatment with a biphasic oral contraceptive containing desogestrel. Horm. Res., 38, 184–189.
135. Kafrissen, M.E. and Corson, S.L. (1992) Comparative review of third-generation progestins. Int. J. Fertil., 37 (Suppl. 2), 104–115.
136. Kannel, W.B. (1987) Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am. Heart. J., 114, 413–419.
137. Katemdahl, D.A., Realini, J.P. and Cohen, P.A. (1992) Oral contraceptive use and cardiovascular disease: is the relationship real or due to study bias? J. Fam. Pract., 35, 147–157.
138. Kauppinen-Mäkelin, R., Kuusi, T., Ylikorkala, O. and Tikkanen, M.J. (1992) Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin. Endocrinol., 36, 203–209.
139. Kay, C.R. (1982) Progestogens and arterial disease — evidence from the Royal College of General Practitioners’ Study. Am. J. Obstet. Gynecol., 142, 762–765.
140. Kelleher, C., Joyce, C., Kelly, G. and Feris, J.B. (1986) Blood pressure alters during the normal menstrual cycle. Br. J. Obstet. Gynaecol, 93, 523–526.
141. Kesserü, E., Albornoz, H., Diaz, M. and Socolsky, R. (1991) Serum lipid variations in women on copper intrauterine devices: triphasic oral contraceptives and monthly injectable contraceptives. Contraception, 44, 235–244.
142. Killick, S.R. (1989) Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil. Steril., 52, 580–582.
143. Killick, S., Eyong, E. and Elstein, M. (1987) Ovarian follicular development in oral contraceptive cycles. Fertil. Steril., 48, 409–413.
144. Killick, S.R., Bancroft, K., Oelbaum, S., Morris, J. and Elstein, M. (1990) Extending the duration of the pill-free interval during combined oral contraception. Adv. Contracept., 6, 33–40.
145. Kirk, J. (1971) Norgestrel and acne. Med. J. Aust., 2, 396.
146. Kirkman, R.J.E., Pedersen, J.H., Fioretli, P. and Roberts, H.E. (1994) Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception, 49, 33–46.
147. Kjær, A., Lebech, A.M., Borggaard, B., Refn, H., Pedersen, L.R., Schierup, L. and Bremmelgaard, A. (1989) Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception, 40, 665–673.
148. Kloosterboer, H.J., van Wayjen, R.G.A and van den Ende, A. (1986) Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism. Contraception, 34, 135–144.
149. Kloosterboer, H.J., van Wayjen, R.G.A. and van den Ende, A. (1987a) Effects of the oral contraceptive combination 0.150 μg desogestrel + 0.020 μg ethinylestradiol on serum lipids including the HDL subfractions. Acta Obstet. Gynecol. Scand., Suppl., 144, 33–36.
150. Kloosterboer, H.J., van Wayjen, R.J.A. and van den Ende, A. (1987b) Effect of three low-dose oral contraceptive combinations on sex hormone binding globulin, corticosteroid binding globulin and antithrombin III activity in healthy women: two monophasic desogestrel combinations (containing 0.020 or 0.030 μg ethinylestradiol) and one triphasic levonorgestrel combination. Acta Obstel. Gynecol. Scand., Suppl., 144, 41–44.
151. Kloosterboer, H.J., Vonk-Noordegraaf, C.A. and Turpijn, E.W. (1988) Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception, 38, 325–332.
152. Koetsawang, S., Charoenvisal, C., Banhamsupawat, L., Singhakovin, S., Kaewsuk, O. and Punnahitanont, S. (1994) Multicentre trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception, in press.
153. Kojima, T., Lindheim, S.R., Duffy, D.M., Vijod, M.A., Stanczyk, F.Z. and Lobo, R.A. (1993) Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives. Am. J. Obstet. Gynecol., 169, 1540–1544.
154. Kotchen, T.A., Kotchen, J.M., Guthrie, G.P. and Cottrill, C.M. (1979) Plasma renin activity, reactivity, concentration and substrate following hypertension during pregnancy — effect of oral contraceptive agents. Hypertension, 1, 355–361.
155. Kovacs, L., Bartfai, G., Apro, G., Annus, J., Bulpitt, C., Belsey, E. and Pinol, A. (1986) The effect of the oral contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary. Contraception, 33, 69–77.
156. Kudzma, D.J., Bradley, E.M. and Goldzieher, J.W. (1972) A metabolic balance study of the effects of an oral contraceptive on weight and body composition. Contraception, 5, 31–37.
157. Kuhl, H., Gahn, G., Romberg, G., März, W. and Taubert, H.D. (1985a) A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters. I. Effects upon sexual hormone levels. Contraception, 31, 583–593.
158. Kuhl, H., Gahn, G., Romberg, G., Althoff, P.H. and Taubert, H.D. (1985b) A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters. II. Effects upon thyroid function, gastrin, STH, and glucose tolerance. Contraception, 32, 97–107.
159. Kuhl, H., Jung-Hoffmann, C. and Heidt, F. (1988a) Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception, 38, 381–390.
160. Kuhl, H., Jung-Hoffmann, C. and Heidt, F. (1988b) Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene. Contraception, 38, 477–486.
161. Kuhl, H., Jung-Hoffmann, C., Weber, J. and Böhm, B.O. (1993a) The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception, 47, 55–68.
162. Kuhl, H., März, W., Jung-Hoffmann, C., Weber, J., Siekmeier, R. and Gross, W. (1993b) Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels. Contraception, 47, 69–83.
163. Kuhnz, W. (1990) Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. Am. J. Obstet. Gynecol., 163, 2120–2127.
164. Kuhnz, W. and Beier, S. (1994) Comparative progestational and androgenic activity of norgestimate and levonorgestrel in the rat. Contraception, 49, 275–289.
165. Kuhnz, W., HOmpel, M., Schütt, B., Louton, T., Steinberg, B. and Gansau, C. (1990) Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design. Horm. Res., 33, 40–44.
166. Kuhnz, W., Back, D., Power, J., Schütt, B. and Louton, T. (1991a) Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design. Horm. Res., 36, 63–90.
167. Kuhnz, W., Sostarek, D., Gansau, C., Louton, T. and Mahler, M. (1991b) Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum. Am. J. Obstet. Gynecol., 165, 596–602.
168. Kuhnz, W., Al-Yacoub, G., Power, J., Orme, M.L.E., Sher, S.E., Back, D.J. and Jutting, G. (1992a) Pharmacokinetics and serum protein binding of 3-ketodesogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. Arzneim.-Forsch., 42, 1142–1146.
169. Kuhnz, W., Schütt, B., Power, J. and Back, D J. (1992b) Pharmacokinetics and serum protein binding of gestodene and 3-ketodesogestrel in women after single oral administration of two different contraceptive formulations. Arzneim.-Forsch., 42, 1139–1141.
170. Kuhnz, W., Blode, H. and Mahler, M. (1994a) Systemic bioavailability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception, 49, 255–263.
171. Kuhnz, W., Schütt, B. and Woloszczak, R. (1994b) Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroids levonorgestrel, 3-keto-desogestrel and gestodene. J. Steroid Biochem. Mol. Biol., 48, 573–580.
172. Lammers, P. and op ten Berg, M. (1991) Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinyl estradiol. Acta Obstet. Gynecol. Scand., 70, 497–500.
173. Landgren, B.M. and Csemiczky, G. (1991) The effect on follicular growth and luteal function of ‘missing the pill’. Contraception, 43, 149–159.
174. Lemay, A., Dodin Dewailly, D., Grenier, R. and Huard, J. (1990) Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d, l-norgestrel. J. Clin. Endocrinol. Metab., 71, 8–14.
175. Lepot, M.R. and Gaspard, U.J. (1987) Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene. Int. J. Fertil., 15–20.
176. Lever, L. and Marks, R. (1990) Current views on the aetiology, pathogenesis and treatment of acne vulgaris. Drugs, 39, 681–692.
177. Levrier, M., Degrelle, H., Bestaux, Y., Bourry-Moreno, M., Brun, J.P. and Sailly, F. (1988) Efficacité sur l’acné des contraceptifs oraux. Rev. Fr. Gynecol. Obstet., 83, 573–576.
178. Lidegaard, Ø. (1993) Oral contraception and risk of a cerebral thromboembolic attack; results of a case-control study. Br. Med. J., 306, 956–963.
179. Lim, K.G., Isles, C.G., Hodsman, G.P., Lever, A.F. and Robertson, J.W.K. (1987) Malignant hypertension in women of childbearing age and its relation to the contraceptive pill. Br. Med. J., 294, 1057–1059.
180. Lis, Y., Spitzer, W.O., Mann, R.D., Cockbum, I., Chukwujindu, J., Thorogood, M., Evans, S., Suissa, S. and Lelorier, J. (1993) A concurrent cohort study of oral contraceptive users from the VAMP Research Bank. Pharmacoepidemiol. Drug Saf., 2, 51–63.
181. Litchfield, R.E and Grunewald, K.K. (1988) Oral contraceptives and fat patterning in young adult women. Hum. Biol., 60, 793–800.
182. Liukko, P. and Erkkola, R. (1989) Serum lipid profiles during long-term oral contraception: effect of two different progestins. Int. J. Feto-Maternal Med., 2, 93–97.
183. Liukko, P., Erkkola, R., Lammintausta, R., Groenroos, M. and Kloosterboer, H.J. (1987) Blood glucose, insulin, growth hormone and glycosylated proteins during two years’ oral contraception with low estrogen combinations. Ann. Chir. Gynaecol., 76 (Suppl. 202), 45–49.
184. Liukko, P., Erkkola, R. and Betgink, E.W. (1988) Progestin-dependent effect on androgen levels during oral contraception. Int. J. Feto-Maternal Med., 1, 15–20.
185. Livshits, G., Weisbort, J., Meshulam, N. and Brunner, D. (1989) Multivariate analysis of the twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study and the usefulness of high density lipoprotein cholesterol percentage. Am. J. Cardiol., 63, 676–681.
186. London, R.S., Chapdelaine, A., Upmalis, D., Olson, W. and Smith, J. (1992) Comparative contraceptive cfficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet. Gynecol. Scand., Suppl., 156, 9–14.
187. Loudon, N.B., Kirkman, R.J.E. and Dewsbury, J.A. (1990) A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. Eur. J. Obstet. Gynecol. Reprod. Biol., 34, 257–266.
188. Lussier-Cacan, S., Xhingesse, M., Desmarais, J.L., Davignon, J., Kafrissen, M.E. and Chapdelaine, A. (1991) Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy. Metabolism, 40, 849–854.
189. Luyckx, A.S., Gaspard, U.J., Romus, M.A., Grigorescu, E, De Meyts, P. and Lefebre, P.J. (1986) Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil. Steril., 45, 635–642.
190. Madden, S., Back, D.J., Martin, C.A. and Orme, M.L.E. (1989) Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br. J. Clin. Pharmacol., 27, 295–299.
191. Makhzangy, M.N., Wynn, V. and Lawrence, D.M. (1979) Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin. Endocrinol., 10, 39–45.
192. Malalino, L.S., Glen, L., Wilson, E.S.B., Leckie, B.J., Murray, G., Weir, D.J. and Robertson, J.I.S. (1988) The effects of low-dose estrogen-progestogen oral contraceptives on blood pressure and the renin-angiotensin system. Curr. Ther. Res., 43, 743–749.
193. Mall-Haefeli, M., Wemer-Zodrow, I., Hubert P. and Weijers, M J. (1982) Klinische und Biochemische Resultate bei der Behandlung mit Marvelon — einem neuen steroidalen Ovulationshemmer. Geburtshilfe Frauenheilkd., 42, 215–222.
194. Mall-Haefeli, M., Wemer-Zodrow, L and Huber, P.R. (1991) Klinische Erfahrungen mit Mercilon und Marvelon unter besonderer Berücksichtigung derOvar-Funktion. Geburtshilfe Frauenheilkd., 51, 34–38.
195. Mammen, E.F. (1982) Oral contraceptives and blood coagulation: a critical review. Am. J. Obstet. Gynecol., 142, 781–790.
196. Manninen, V., Elo, M.O., Frick, M.H., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, R, Koskinen, P., Nikkilä, E.A., Mäenpää, H., MSlkönen, M., Mänttäri, M., Norola, S., Pastemack, A., Pikkarainen, J., Romo, M. and Sjöblom, T. (1988) Lipoprotein alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J. Am. Med. Assoc., 260, 641–651.
197. Marchesoni, D., Mozzanega, B., Fiscon, D., Aprilis, M. and Maggino, T. (1988) Hormonal contraception in peri me no pause. J. Gynaecol. Endocrinol., 4, 17–18.
198. März, W., Gross, W., Gahn, G., Romberg, G., Taubert, H.D. and Kuhl, H. (1985) A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am. J. Obstet. Gynecol., 153, 287–293.
199. März, W., Jung-Hoffmann, C., Heidt, F., Gross, W. and Kuhl, H. (1990) Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel. Contraception, 41, 245–258.
200. Massafra, C., Capitani, S., Bernabei, A. and Scillone, L. (1988) Effets combinés d’une association contraceptive éthinylestradiol/désogestrel sur les lipides sériques et les paramètres des fonctions hépatiques et de la coagulation. Rev. Fr. Gynecol. Obstet., 83, 251–255.
201. Massafra, C., Butini, P., Cavion, M.A., Minuto, S.M. and Colombini, G. (1993) Evaluation of risk of thrombosis during use of low-dose ethinylestradiol-desogestrel oral contraceptive. Adv. Contrarept., 9, 195–203.
202. Mayer, H.O., Kostner, G., Tscherne, G. and Desoye, G. (1988) Vergleich des Einflusses eines Desogestrel-bzw. Levonorgestrelhaltigen KombinationsprSparates auf Lipid-Stoffwechsel, Serumtestosteron und SHBG. Fertilität, 4, 173–178.
203. McAreavy, D., Cumming, A.M.M., Boddy, K, Brown, J.J., Fraser, R., Leckie, B.J., Lever, A.F., Morton, J.J., Robertson, J.I. and Williams, E.D. (1983) The renin-angiotensin system and total body sodium and potassium in hypertensive women taking oestrogen-progestagen oral contraceptives. Clin. Endocrinol., 18, 111–118.
204. McGuire, J.L., Phillips, A., Hahn, D.W., Tolman, E.L., Flor, S. and Kafrissen, M.E. (1990) Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am. J. Obstet. Gynecol., 163, 2127–2131.
205. McKenna, T.J. (1991) The use of anti-androgens in the treatment of hirsutism. Clin. Endocrinol., 35, 1–3.
206. Meade, T.W., Chakrabarti, R., Haines, A.P., Howarth, D.J., North, W.R.S. and Stirling, Y. (1977) Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet, 2, 948–951.
207. Meade, T.W., Greenberg, G. and Thompson, S.G. (1980) Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-g oestrogen preparations. Br. Med. J., 280, 1157–1161.
208. Melis, G.B., Fruzzetti, F., Paoletti, A.M., Carmassi, F. and Fioretti, P. (1984) Fibrirtopeptide A plasma levels during low-estrogen oral contraceptive treatment. Contraception, 30, 575–583.
209. Melis, G.B., Fruzzeti, F., Nicoletti, I., Ricci, C., Lammers, P., Atsma, W.J. and Fioretti, P. (1991) A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol and a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception, 43, 23–31.
210. Meulenberg, P.M.M., Ross, H.A., Swinkels, L.M.J.W. and Benraad, T.J. (1987) The effect of oral contraceptives on plasma-free and salivary Cortisol and cortisone. Clin. Chim. Acta, 165, 379–385.
211. Miccoli, R., Orlandi, M.C., Fnizzetti, F., Giampietro, O., Melis, G., Ricci, C., Bertolotto, A., Fioretti, P., Navalesi, R. and Masoni, A. (1989) Metabolic effects of three new low-dose pills: a six-month experience. Contraception, 39, 643–652.
212. Morris, S.E, Groom, G.V., Cameron, E.D., Buckingham, M.S., Everitt J.M. and Elstein, M. (1979) Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate (‘Microgynon 30’) omission. Contraception, 20, 61–69.
213. Nappi, C., Farace, M.J., Leone, F., Minutolo, M., Tommaselli, A.P. and Montemagno, U. (1987) Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhoea and ovarian hyperandrogenism. Eur. J. Gynecol. Obstet. Reprod. Biol., 25, 209–219.
214. National Institutes of Health Consensus Development Panel on triglyceride, high-density lipoprotein, and coronary heart disease (1993) Triglyceride, high-density lipoprotein, and coronary heart disease. J. Am. Med. Assoc., 269, 505–510.
215. Nichols, M., Robinson, G., Bounds, W., Newman, B. and Guillebaud, J. (1993) Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception, 47, 367–376.
216. Nielsen, C.H., Poulsen, H.K., Teisner, B., Thorsen, P., Hau, J. and Westergaard, J.G. (1993) Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives. Eur. J. Obstet. Gynecol. Reprod. Biol., 51, 63–71.
217. Nilsson, L. and Solvell, L. (1967) Clinical studies on oral contracepti ves: a randomized, double-blind, cross-over study of 4 different preparations. Acta Obstet. Gynecol., Scand., Suppl, 8, 3–31.
218. Notelovitz, M., Levenson, I., McKenzie, L., Lane, D. and Kitchens, C.S. (1985) The effects of low-dose oral contraceptives on coagulation and fibrinolysis in two high-risk populations: young female smokers and older premenopausal women. Am. J. Obstet. Gynecol., 152, 995–1000.
219. Oddens, B.J., Arnolds, H.T., van Maris, M.G.M. and van Lunsen, H.W. (1994) The dynamics of oral contraceptive use: starting, discontinuation and switching in The Netherlands 1990–93. Adv. Contracept., 10, 167–174.
220. Omsjö, L.H., Oian, P., Maltau, J.M. and Osterud, B. (1989) Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis. Acta Obstet. Gynecol. Scand., 68, 27–30.
221. Orme, M., Back, D.J., Ward, S. and Green, S. (1991) The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception, 43, 305–316.
222. Palatsi, R., Hirvensalo, E., Liukko, P., Malmiharju, T., Mattila, L., Riihiluoma, P. and Ylöstalo, P. (1984) Serum total and unbound testosterone and sex hormone binding globulin in female acne patients treated with two different oral contraceptives. Acta Dermatol. Venereol., 64, 517–523.
223. Palatsi, R., Reinilä, M. and Kivinen, S. (1986) Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and Cortisol before and after oral contraceptive treatment in female acne. Acta Dermatol. Venereol., 66, 225–230.
224. Pansini, F., Ferrari, C., Guerra, S., Bassi, P., Guzzinati, N., Cocilovo, G. and Mollica, G. (1987) Advantage of desogestrel containing pill in oral contraception: influence on blood lipids and LCAT activity. Clin. Exp. Obstet. Gynecol., 14, 136–139.
225. Pazzucconi, F., Malavasi, B., Galli, G., Franceschini, G., Calabresi, L. and Sirtori, C.R. (1991) Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin. Pharmacol. Ther., 49, 278–284.
226. Petersen, K.R., Skouby, S.O., Dreisler, A., Kuhl, K. and Svenstrup, B. (1988) Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two new oral contraceptives containing gestoden and desogestrel. Acta Obstet. Gynecol. Scand., 67, 37–41.
227. Petersen, K.R., Skouby, S.O. and Pedersen, R.G. (1991) Desogestrel and gestodene in oral contraceptives: 12 months’ assessment of carbohydrate and lipid metabolism. Am. J. Obstet. Gynecol., 78, 666–672.
228. Petersen, K.R., Sidelmann, J., Skouby, S.O. and Jespersen, J. (1993) Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am. J. Obstet. Gynecol., 168, 32–38.
229. Porcile, A. and Gallardo, E (1991a) Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil. Steril., 55, 877–881.
230. Porcile, A. and Gallardo, E (1991b) Oral contraceptives containing desogestrel in the maintainance of the remission of hirsutism: monthly versus bimonthly treatment. Contraception, 44, 533–540.
231. Prasad, R.N.V., Liew, D. and Ratnam, S.S. (1989) Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women. Contraception, 39, 21–35.
232. Pyörälä, K., Savolainen, E., Kaukola, S. and Haapakoski, J. (1985) Plasma insulin as coronary heart disease risk factor relationship to other risk factors and predictive value during 9½-year follow-up of the Helsinki Policemen Study population. Acta Med. Scand., Suppl., 701, 38–52.
233. Quehenberger, P., Kapiotis, S., Pärtan, C., Schneider, B., Wenzel, R., Gaiger, A. and Speiser, W. (1993) Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann. Hematol., 67, 33–36.
234. Rabe, T., Runnebaum, B., Kohlmeier, M., Harenberg, J., Weicker, H. and Unger, R. (1987) Clinical and metabolic effects of gestodene and levonorgestrel. Int. J. Fertil., 29–44.
235. Ráckóczi, I., Gerö, G., Demeter, J. and Gáti, I. (1985) Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Arzneim-Forsch., 35, 630–633.
236. Ramcharan, S., Pellegrin, F.A., Ray, R., Hsu, J.P. and Vessey, M.P. (1981) The Walnut Creek Contraceptive Drug Study. Center for Population Research, Bethesda, MD, USA, Vol. III.
237. Rebuffé-Scrive, M., Cullberg, G., Lundberg, P.A., Lindstedt, G. and Bjömtorp, P. (1989) Anthropometric variables and metabolism in polycystic ovarian disease. Horm. Metab. Res., 21, 391–397.
238. Refn, H., Kjter, A., Lebech, A.M., Borggaard, B., Schierup, L. and Bremmelgaard, A. (1990) Metabolic changes during treatment with two different progestogens. Am. J. Obstet. Gynecol., 163, 374–377.
239. Rekers, H. (1988) Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet. Gynecol. Scand., 67, 171–174.
240. Robinson, G.E, Bounds, W., Mackie, I.J., Stocks, J., Burren, T., Machin, S.J. and Guillebaud, J. (1990) Changes in metabolism induced by oral contraceptives containing desogestrel and gestodene in older women. Contraception, 42, 263–273.
241. Rojanasakul, A., Chailurkit, L., Sirimongkolkasem, R. and Chaturachinda, K. (1987) Effects of combined desogestrel-ethinylestradiol treatment on lipid profiles in women with polycystic ovarian disease. Fertil. Steril., 48, 581–585.
242. Rosenberg, M.J. and Long, S.C. (1992) Oral contraceptive and cycle control: a critical review of the literature. Adv. Contracept., 8 (Suppl. 1), 35–45.
243. Royal College of General Practitioners (1967) Oral contraception and thromboembolic disease. J. R. Coll. Gen. Pract., 13, 267–279.
244. Royal College of General Practitioners (1974) Oral Contraceptives and Health. Pitman Medical, London, UK.
245. Royal College of General Practitioners (1978) Oral contraceptives, venous thrombosis, and varicose veins: Royal College of General Practitioners’ Oral Contraception Study. J. R. Coll. Gen. Pract., 28, 393–399.
246. Royal College of General Practitioners’ Oral Contraception Study (1977) Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet, 1, 624.
247. Rozenbaum, H. (1988) Inhibition of ovarian function by a gestodene triphasic combination. Rev. Fr. Gynecol. Obstet., 83, 449–452.
248. Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, J.G. and Clift, S.M. (1991) Inhibition of early atherosclerosis in transgenic mice by human apolipoprotein Al. Nature, 353, 265–267.
249. Runnebaum, B., Grunwald, K. and Rabe, T. (1992) The efficacy and tolerability of norgestimate ethinyl estradiol (250) μg norgestimate/35 Hg of ethinyl estradiol: results of an open, multicenter study of 59,701 women. Am. J. Obstet. Gynecol., 166, 1963–1968.
250. Ruutiainen, K. (1986) The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women. Int. J. Gynaecol. Obstet., 24, 361–368.
251. Samsioe, G. (1982) Study on the effect of 30 μg ethinylestradiol (EE) + 150 Hg desogestrel on lipid and lipoprotein metabolism in healthy volunteers, also in comparison with 30 μg EE + 150 μg levonorgestrel. Acta Obstet. Gynecol. Scand., Suppl., 111, 55–60.
252. Sapire, K.E, Berger, G.M.B, and Maritz, J.S. (1991) The clinical and biochemical effects of two combination oral contraceptive agents. S. Afr. Med. J., 79, 376–379.
253. Shaw, G., Killick, S. and Elstein, M, (1992) Assessment of ovarian activity in a gestodene containing triphasic oral contraceptive. Br. J. Fam. Plann., 18, 76–78.
254. Shoupe, D. (1994) Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel or norethindrone. Obstet. Gynecol., 83, 679–686.
255. Si, S., Jun-kang, C., Pei-juan, Y., Mei-li, H., La-mei, L., Bao-chuan, F., Rekers, H. and Fotherby, K. (1992) A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception, 45, 523–532.
256. Silbergeld, S., Brast, N. and Noble, E.P. (1971) The menstrual cycle: a double-blind study of symptoms, mood and behavior, and biochemical variables using Enovid and placebo. Psychosom. Med., 33, 411–428.
257. Sirimongkolkasem, R., Rojanasakul, A., Phiromsawat, S. and Chailurkit, L. (1988) Comparative effects of combined oral contraceptives containing desogestrel or levonorgestrel on serum lipids, lipoproteins and sex hormone binding globulin in healthy women. J. Med. Assoc. Thailand., 71 (Suppl. 2), 68–73.
258. Sirtori, C.R., Calabresi, L., Franceschini, G., Gianfranceschi, G., Zoppi, F., Winkler, S., Bilotta, P. and Zampetti, A. (1990) Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women. Atherosclerosis, 84, 203–211.
259. Sisenwine, S.F., Liu, A.L., Kimmel, H.B. and Ruelius, H.W. (1977) The conversion of d-norgestrel-3-oxime-17-acetate to d-norgestrel in female rhesus monkeys. Contraception, 15, 25–37.
260. Sobbrio, G.A., Granata, A., D’Arrigo, F., Arena, D., Trimarchi, F., Granese, D. and Pulle, C. (1989) Short term treatment of hirsutism related to micropolycystic ovary syndrome with a combination type oral contraceptive containing desogestrel. Acta Eur. Fertil., 20, 35–37.
261. Sobbrio, G.A., Granata, A., D’Arrigo, F., Arena, D., Panacea, A., Trimarchi, F., Granese, D. and Pulle, C. (1990) Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. Acta Eur. Fertil., 21, 139–141.
262. Sobbrio, G.A., Granata, A., Granese, D., D’Arrigo, F., Panacea, A., Nicita, R., Pulle, C. and Trimarchi, F. (1991) Sex hormone binding globulin, Cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen. Clin. Exp. Obstet. Gynecol., 18, 43–45.
263. Solerte, S.B., Fioravanti, M., Spinillo, A., Capuzzo, E., Iasci, A., Mastrolilli, M., Berard, P., Reboli, P., Ferrari, E and Guaschino, S. (1993) Hemorheological, hemostatic and metabolic long-term (24 months) study of young women taking a monophasic pill containing gestodene and ethinylestradiol. Ital. J. Gynaecol. Obstet., 5, 85–91.
264. Spellacy, W.N., Buhi, W.C. and Birk, S.A. (1972) The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies in one hundred and seventy women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am. J. Obstet. Gynecol., 114, 378–392.
265. Spellacy, W.N., Buhi, W.C. and Birk, S.A. (1982) The effects of two years of mestranol treatment on carbohydrate metabolism. Metabolism, 31, 1006–1008.
266. Spellacy, W.N., Tsibris, J.C.M., Hunter-Bonner, D.L., Smalling, S., Chez, R.A., Angel, J.L. and O’Brien, W.F. (1992) Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinylestradiol. Contraception, 45, 533–539.
267. Spitzer, W.O., Thorogood, M. and Heinemann, L. (1993) Trinational case-control study of oral contraceptives and health. Pharmacoepidemiol. Drug Saf., 2, 21–31.
268. Steinmetz, A., Bauer, K., Jurgensen, R. and Kaffamik, H. (1990) Low-dose oral contraceptives lower plasma levels of apolipoprotein E Eur. J. Obstet. Gynecol. Reprod. Biol., 37, 155–162.
269. Suissa, S., Hemmelgarn, B., Spitzer, W.O., Brophy, J., Collet, J.P., Côte, R., Downey, W., Edouard, L., Leclerc, W. and Paltiel, O. (1993) The Saskatchewan Oral Contraceptive Cohort Study of oral contraceptive use and cardiovascular risk. Pharmacoepidemiol. Drug Saf., 2, 33–49.
270. Taylor, D.R., Anthony, F.W. and Dennis, K.J. (1986) Suppression of ovarian function by Microgynon 30 in day 1 and day 5 ‘starters’. Contraception, 33, 463–471.
271. Tayob, Y., Robinson, G., Adams, J., Nye, M., Whitelaw, N., Shaw, R.W., Jacobs, H.S. and Guillebaud, J. (1990) Ultrasound appearance of the ovaries during the pill-free interval. Br. J. Fam. Plann., 16, 94–96.
272. Thorogood, M., Mann, J., Murphy, M. and Vessey, M. (1992) Risk factors for fatal venous thromboembolism in young women: a case control study. Int. J. Epidemiol., 21, 48–52.
273. Timmer, C.J., Apter, D. and Voortman, G. (1990) Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. Contraception, 42, 629–642.
274. Trienekens, P.H., Schmidt, N.A. and Thijssen, J.H.R (1986) The effect of age, weight-related parameters and hormonal contraceptives on andrological assays. Contraception, 33, 503–517.
275. Trossarelli, G.F., Bordon, R., Genarelli, G.L. and Carta, Q. (1991) An open prospective study on the effects on carbohydrate metabolism of an oral monophasic contraceptive containing gestodene (WL-70). Contraception, 43, 423–433.
276. Tuimala, R., Korhonen, M. and Kortesluoma, M. (1987) Effects of the oral contraceptive combination 0.150 μg desogestrel + 0.020 μg ethinylestradiol on serum lipids, SHBG, glycosylated proteins and plasma antithrombin III activity in healthy women. Acta Obstet. Gynecol. Scand., Suppl., 144, 37–39.
277. van den Ende, A., Lutjens, A., van Wayjen, R.G.A. and Kloosterboer, H.J. (1987) Effect of desogestrel/ethinylestradiol on carbohydrate metabolism. Acta Obstet. Gynecol. Scand., Suppl., 144, 29–32.
278. van der Vange, N. (1988) Ovarian activity during low dose oral contraceptives. In Chamberlain, G. (ed.), Contemporary Obstetrics and Gynaecology. Butterworths, London, UK, pp. 315–326.
279. van der Vange, N., Kloosterboer, H J. and Haspels, A.A. (1987a) Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am. J. Obstet. Gynecol., 156, 918–922.
280. van der Vange, N., Kloosterboer, H J. and Haspels, A.A. (1987b) Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractions. Br. J. Obstet. Gynaecol., 94, 559–567.
281. van der Vange, N., Blankenstein, M.A., Kloosterboer, H.J., Haspels, A.A. and Thijssen, J.H.H. (1990) Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception, 41, 345–354.
282. Vekemans, M., Grippa, J., Capel, P. and Fondu, P. (1987) The effect of two low-dose contraceptives containing ethinylestradiol and desogestrel or d-norgestrel on blood clotting factors. Curr. Ther. Res., 42, 1109–1118.
283. Venturoli, S., Porcu, E., Gammi, L., Fabbri, R., Paradisi, R., Flamigni, C., Patrono, D., Capelli, M. and Paoletti, C. (1988) The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence. Acta Eur. Fertil., 19, 129–134.
284. Vessey, M.P. (1988) Epidemiological studies of lower dose oral contraceptives. Presented at the XII World Congress of Gynecology and Obstetrics, Rio de Janeiro, Brazil, October 26, 1988.
285. Vessey, M.P. and Doll, R. (1968) Investigation of relation between the use of oral contraceptives and thromboembolic disease. Br. Med. J., 2, 199–205.
286. Viinikka, L (1979) Metabolism of a new synthetic progestogen. Org 2969, by human liver in vitro. J. Steroid Biochem., 10, 353–357.
287. Viinikka, L., Ylikorkola, O., Vihko, R., Wijnand, H.P., Booij, M. and van der Veen, F. (1979) Metabolism of a new synthetic progestogen. Org 2969, in female volunteers. Pharmacokinetics after an oral dose. Eur. J. Clin. Pharmacol., 15, 349–355.
288. Viinikka, L., Ylikorkala, O., Vihko, R., Hasenack, H.G. and Nieuwenhuyse, H. (1980) Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. Acta Endocrinol., 93, 375–379.
289. Volpe, A., Silferi, M., Genazzani, A.D. and Genazzani, A.R. (1993) Contraception in older women. Contraception, 47, 229–239.
290. Volpe, A., Silferi, M., Mauri, A., Deiana, P., Angioni, S., Grasso, A. and Genazzani, A.R. (1994) Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. Eur. J. Obstet. Gynecol. Reprod. Biol., 53, 205–209.
291. Voorhoof, L, Rosseneu, M., Caster, H. and de Keersgieter, W. (1986) Metabolic effects of a biphasic oral contraceptive preparation containing ethinyloestradiol and desogestrel on serum lipoproteins and apoproteins. J. Endocrinol, 111, 191–196.
292. Wallace, R.B., Heiss, G., Burrows, B. and Graves, K. (1987) Contrasting diet and body mass among users and non-users of oral contraceptives and exogenous estrogens: the Lipid Research Clinic’s Program Prevalence Study. Am. J. Epidemiol., 125, 854–859.
293. Walling, M. (1992) A multicenter efficacy and safety study of an oral contraceptive containing 150 μg desogestrel and 30 μg ethinyl estradiol. Contraception, 46, 313–326.
294. Weber-Diehl, F., Unger, R. and Lachnit, U. (1992) Triphasic combination of ethinyl estradiol and gestodene — long-term cliriical trial. Contraception. 46, 19–27.
295. Weir, R.J., Briggs, E., Mack, A., Naismith, L., Taylor, L. and Wilson, E (1974) Blood pressure in women taking oral contraceptives. Br. Med. J., 1, 533–535.
296. Wheeler, J.M. and Malinak, L.R. (1991) Complexion changes in oral contraceptive users. J. Reprod. Med., 36, 340–344.
297. Wiegratz, I., Jung-Hoffmann, C., Siekmeier, R., März, W., Gross, W. and Kuhl, H. (1992) A prospective randomized trial of two low-dose oral contraceptives: effects on serum lipid and lipoprotein levels. Adv. Contracept., 8, 175–176.
298. Wiseman, A., Bowie, J., Cogswell, D., Dewsbury, J., Hamilton, M., Hutchinson, F., Kirkman, R., Loudon, N., Lincoln, R., Lyons, M., Pullen, D. and Wilson, E (1984) Marvelon: clinical experience in the UK. Br. J. Fam. Plann., 10, 38–42.
299. Woodward, R.K, (1974) Acne stimulation by Oral. Arch. Dermatol., 110, 812.
300. Wynn, V. (1991) Oral contraceptives and coronary heart disease. J. Reprod. Med., 36, 219–225.
301. Ylikorkala, O., Kuusi, T., Tikkanen, M.J. and Viinikka, L. (1987) Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J. Clin. Endocrinol. Metab., 65, 1238–1242
302. Zeiher, A.M., Schächinger, V., Hohnloser, S.H., Sambier, B. and Just, H. (1994) Coronary atherosclerotic wall thickening and vascular reactivity in humans. Circulation, 89, 2525–2532.